Myeloproliferative Neoplasms News

Amit Maity, MD, PhD, has been appointed chair of the department of radiation oncology for Spencer Fox Eccles School of Medicine at University of Utah.

ASH announced the 36 recipients of the society’s 2022 Scholar Awards.

Fox Chase Cancer Center announced two faculty appointments.

Septic shock remained significantly associated with increased 28-day mortality among patients with hematologic malignancies, according to study results published in Journal of the National Comprehensive Cancer Network.

Faith E. Davies, MD, has been appointed the inaugural director of Center for Blood Cancers at NYU Langone Health’s Perlmutter Cancer Center.

A randomized phase 3 trial of momelotinib for patients with pretreated myelofibrosis met all primary and key secondary endpoints, according to topline data released by the agent’s manufacturer.

Depletion of naive T cells from peripheral blood stem cell grafts resulted in very low incidence of severe acute and any graft-versus-host disease in three phase 2 clinical trials, according to a study in Journal of Clinical Oncology.

Older patients with B-cell malignancies diagnosed with COVID-19 had a substantially higher risk for death than their counterparts aged 60 years or younger, according to study results published in JCO Oncology Practice.

In this video, Aaron T. Gerds, MD, MS, discusses data presented at ASH Annual Meeting and Exposition about the long-term treatment with pacritinib in patients with advanced myelofibrosis.

Aaron T. Gerds, MD, MS, speaks with Healio about the safety of pacritinib in patients with myelofibrosis and severe thrombocytopenia.